Nolan Sean P., CEO of Taysha Gene Therapies ($TSHA), made two open market sales of company shares over the past year, totaling about $840 thousand. His most recent sale occurred on January 26, 2026. These sales rank 5,321st among 11,678 insiders in the database, where the average is $8.6 million across 6.37 transactions. He reported no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| July 21, 2020 | Ventas, Inc. | $VTR | Nolan Sean P. | Director | P | Common Stock | 37 | $34.21 | 24,284.0000 | 0 | 0.15% | 0.00% |
| April 20, 2020 | Ventas, Inc. | $VTR | Nolan Sean P. | Director | P | Common Stock | 50 | $27.70 | 24,247.0000 | 0 | 0.21% | 0.00% |
| July 21, 2020 | Ventas, Inc. | $VTR | Nolan Sean P. | Director | P | Common Stock | 27 | $34.21 | 24,284.0000 | 0 | 0.11% | 0.00% |
| April 20, 2020 | Ventas, Inc. | $VTR | Nolan Sean P. | Director | P | Common Stock | 36 | $27.70 | 24,257.0000 | 0 | 0.15% | 0.00% |
| Jan. 23, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nolan Sean P. | Chief Executive Officer | S | Common Stock | 136789 | $4.75 | 4,485,114.0000 | 353,309,524 | 2.96% | 0.04% |
| Jan. 26, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nolan Sean P. | Chief Executive Officer | S | Common Stock | 41312 | $4.61 | 4,443,802.0000 | 353,309,524 | 0.92% | 0.01% |
| Jan. 12, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nolan Sean P. | Chief Executive Officer | A | Employee Stock Option (right to buy) | 648000 | $0.00 | 648,000.0000 | 353,309,524 | 9999.99% | 0.18% |
| Jan. 12, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nolan Sean P. | Chief Executive Officer | A | Common Stock | 1008000 | $0.00 | 4,621,903.0000 | 353,309,524 | 27.89% | 0.29% |
| May 13, 2025 | Ventas, Inc. | $VTR | Nolan Sean P. | Director | A | Common Stock | 2882 | $64.18 | 24,134.0000 | 437,139,980 | 13.56% | 0.00% |
| Jan. 2, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nolan Sean P. | Chief Executive Officer | A | Employee Stock Option (right to buy) | 892500 | $0.00 | 892,500.0000 | 250,134,421 | 9999.99% | 0.36% |
| Jan. 2, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nolan Sean P. | Chief Executive Officer | A | Common Stock | 892500 | $0.00 | 3,613,903.0000 | 250,134,421 | 32.80% | 0.36% |
| May 14, 2024 | Ventas, Inc. | $VTR | Nolan Sean P. | Director | A | Common Stock | 3648 | $47.96 | 21,252.0000 | 0 | 20.72% | 0.00% |
| Jan. 2, 2024 | Taysha Gene Therapies, Inc. | $TSHA | Nolan Sean P. | Chief Executive Officer | A | Employee Stock Option (right to buy) | 1184688 | $0.00 | 1,184,688.0000 | 116,121,482 | 9999.99% | 1.02% |
| Jan. 2, 2024 | Taysha Gene Therapies, Inc. | $TSHA | Nolan Sean P. | Chief Executive Officer | A | Common Stock | 1184688 | $0.00 | 2,721,403.0000 | 116,121,482 | 77.09% | 1.02% |